Association of metabolic syndrome with schizophrenia

Bajaj, Sarita; Varma, Anurag; Srivastava, Anubha; Verma, A.K.

doi:10.4103/2230-8210.117238

Cited by 10 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, other studies from Japan [ 13 ], Venezuela [ 14 ], and Italy [ 15 ] did not show that antipsychotics increase the risk of MetS compared to control subjects. Bajaj et al (2013) showed a positive correlation between the duration of treatment and the prevalence of MetS among those taking SGA [ 16 ]. In addition, Gautam and Meena (2011) reported that 11.66% of the patients with schizophrenia developed MetS after four months of being on antipsychotics [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study

et al. 2018

View full text Add to dashboard Cite

BackgroundMetabolic abnormalities are common in patients maintained on antipsychotics. These abnormalities increase the risk of cardiovascular diseases and mortality in this population. The aim of this study is to assess the prevalence of metabolic syndrome (MetS) in subjects maintained on antipsychotics relative to controls in Qatar, and to assess the factors contributing to the development of MetS.MethodsA cross sectional design was used to collect data and fasting blood samples from subjects maintained on antipsychotics for at least six months (n = 112) and from a control group (n = 114). The groups were compared in regard to prevalence of MetS, and multiple regression analysis was used to determine the risk factors in each group.ResultsThe two groups (antipsychotics vs. control) were similar in regard to age (35.73 ± 10.28 vs. 35.73 ± 8.16 years) and gender ratio. The MetS was higher among the subjects on antipsychotics, but this difference did not reach statistical significance. Blood pressure (BP) was significantly higher in the antipsychotics group and BMI was the major risk factor to develop MetS in this group.ConclusionsThe prevalence of MetS in both groups is high and mostly attributed to obesity and high BP. Public health interventions are needed to address this major health problem overall. Larger studies are needed to further assess the impact of antipsychotics and mental illness on the development of MetS.

show abstract

Section: Introductionmentioning

confidence: 99%

The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…[61011121314] The criteria for MS were satisfied by 29.3% of our patients. This was similar to the findings of Bajaj et al .…”

Section: Discussionmentioning

confidence: 95%

“…The prevalence of MS in schizophrenia patients from India varies from 12% to 36%. [ 4 5 6 ] Assuming the prevalence in Assam to be 25%, we calculated the required sample size with a 95% confidence interval (CI) and 10% margin of error. On this basis, it was found that at least 73 patients would be needed.…”

Section: Methodsmentioning

confidence: 99%

“…Often dubbed as the “heart disease capital” and “diabetic capital” of the world, India is a major hotspot for cardiometabolic abnormalities. Although there are some reports on the prevalence of MS in schizophrenia from certain parts of India,[ 4 5 6 ] data from Northeast are lacking. Assam is the most populated state in Northeast India and has a sizeable burden of schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and predictors of metabolic syndrome in schizophrenia patients from Assam

Das¹,

Bora

Baruah³

et al. 2017

Indian J Psychiatry

View full text Add to dashboard Cite

Background:Metabolic abnormalities contribute enormously to morbidity and mortality in schizophrenia.Objectives:Our objectives were to determine the (i) prevalence of metabolic syndrome (MS); and (ii) predictors for MS in schizophrenia patients from Assam.Materials and Methods:Seventy-five schizophrenia patients were evaluated for MS. Risk factors were assessed by odds ratios (ORs) with 95% confidence intervals (CIs).Results:Fifty-nine patients (78.7%) had a metabolic abnormality. Twenty-two patients (29.3%, 95% CI: 19.9%–40.8%) fulfilled the criteria for MS. Female gender (adjusted OR = 7.8, 95% CI: 1.7–36.4), smoking (adjusted OR = 7.9, 95% CI: 1.7–35.8), family history of chronic lifestyle disease (adjusted OR = 4.4, 95% CI: 1.3–15.2), and atypical antipsychotic use (adjusted OR = 4.3, 95% CI: 1.1–16.9) significantly predicted MS.Conclusion:Metabolic abnormalities exist widely in schizophrenics from Assam. Females, smokers, and those with family history of chronic diseases and using atypical antipsychotics are at greater risk.

show abstract

“…The association of MetS and hypertension,[ 18 ] coronary artery disease (CAD),[ 19 ] chronic obstructive pulmonary disease,[ 20 ] polycystic ovarian disease,[ 21 ] thyroid disease,[ 22 ] and psychiatric disorder[ 23 ] is well-described in the literature. Because of the relative paucity of randomized trials on the impact of the MetS on sexual dysfunction, most of the data were collected from cross-sectional or longitudinal studies, where association was observed but not a causation.…”

Section: Introductionmentioning

confidence: 99%

Metabolic syndrome: An independent risk factor for erectile dysfunction

Saran

Bharti

Gutch

et al. 2015

Indian J Endocr Metab

View full text Add to dashboard Cite

Objective:The objective was to determine the role of various components of metabolic syndrome (MetS) as independent risk factor for erectile dysfunction (ED).Materials and Methods:A total of 113 subjects of MetS, as recommended by recent IDF and AHA/NHLBI joint interim statement were selected for study who presented for ED. After doing Anthropometric examination, fasting laboratory assay for fasting plasma glucose (FPG), fasting insulin, hemoglobin A1c, triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and 2 h oral glucose tolerance test (OGTT) was done. Erectile function was assessed by completing questions one through five of the International Index of Erectile Function (IIEF-5). A multiple linear regression analysis was carried out on 66 subjects with IIEF-5 score as dependent variable and components of MetS FPG, 2 h OGTT, TG, HDL, and waist circumference as independent variables.Results:Using a multiple linear regression analysis, we observed that presence of the various components of MetS was associated with ED and a decrease IIEF-5 score and this effect was greater than the effect associated with any of the individual components. Of the individual components of the MetS, HDL (B = 0.136; P = 0.004) and FPG (B = −0.069; P = 0.007) conferred the strongest effect on IIEF-5 score. However, overall age had most significant effect on IIEF-5 score.Conclusion:It is crucial to formulate strategies and implement them to prevent or control the epidemic of the MetS and its consequences. The early identification and treatment of risk factors might be helpful to prevent ED and secondary cardiovascular disease, including diet and lifestyle interventions.

show abstract

Association of metabolic syndrome with schizophrenia

Cited by 10 publications

References 12 publications

The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study

The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study

Prevalence and predictors of metabolic syndrome in schizophrenia patients from Assam

Metabolic syndrome: An independent risk factor for erectile dysfunction

Contact Info

Product

Resources

About